Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

David Grimwade, Sylvie Freeman

    Research output: Contribution to journalArticlepeer-review

    Fingerprint

    Dive into the research topics of 'Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?'. Together they form a unique fingerprint.

    Medicine & Life Sciences